Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Erectile dysfunction
Autore:
McMahon, CG;
Indirizzi:
N Shore Private Hosp, Sydney, NSW, Australia N Shore Private Hosp Sydney NSW Australia e Hosp, Sydney, NSW, Australia
Titolo Testata:
MEDICAL JOURNAL OF AUSTRALIA
fascicolo: 9, volume: 173, anno: 2000,
pagine: 492 - 497
SICI:
0025-729X(20001106)173:9<492:ED>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSURETHRAL ALPROSTADIL; INJECTION THERAPY; SILDENAFIL; PROSTAGLANDIN-E1; MEN; PAPAVERINE; PREVALENCE; EFFICACY; VIAGRA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: McMahon, CG N Shore Private Hosp, Suite 11,Level 3,1 Westbourne St, St Leonards, NSW 2065, Australia N Shore Private Hosp Suite 11,Level 3,1 Westbourne St St Leonards NSW Australia 2065
Citazione:
C.G. McMahon, "Erectile dysfunction", MED J AUST, 173(9), 2000, pp. 492-497

Abstract

Erectile dysfunction (ED) is a common condition and can usually be managedpharmacologically, with drugs delivered by intracavernosal injection (ICI), transurethrally or orally. The cardiovascular status of the patient and his overall fitness for renewed sexual activity must be assessed before treatment for ED is initiated. The efficacy or sildenafil is related to the extent and severity of ED, and is significantly reduced in patients with severe vasculogenic ED, ED associated with diabetes and after radical prostatectomy. Alprostadil (prostaglandin E-1) is the drug of first choice in patients treated with ICI; it is effective in 72.6% of men with ED and is associated with a low risk of priapism and cavernosal fibrosis. Transurethral alprostadil is significantly fess effective than alprostadilICI, producing improved erections in 30%-40%, but rigid erections in only 10%, of men with ED. There is Level II evidence that:alprostadil ICI is an effective treatment for EDpapaverine ICI is associated with a high risk of cavernosal fibrosis and priapismpapaverine ICI should be restricted to informed patients refractory to treatment with alprostadil ICItransurethral alprostadil is less effective than alprostadil ICIsildenafil is an effective treatment for ED.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 10:31:54